Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves First Generic Strattera for ADHD

FDA news release; 2017 May 30

The US Food and Drug Administration (FDA) has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Indications: Strattera is a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Dosage/administration: Dosage is as follows:

  • Children and adolescents ≤70 kg—initial daily dose, 0.5 mg/kg; target total daily dose, 1.2 mg/kg; maximum total daily dose, 1.4 mg/kg.
  • Children and adolescents >70 kg and adults—initial daily dose, 40 mg; target total daily dose, 80 mg; maximum total daily dose, 100 mg.

Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of atomoxetine.

Adverse reactions: Most common adverse reactions (≥5% and at least twice the incidence of placebo patients):

  • Children and adolescents—Nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence.
  • Adults—Constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation.


US Food and Drug Administration. FDA approves first generic Strattera for the treatment of ADHD. FDA Web site. May 30, 2017. Accessed June 1, 2017.

This Week's Must Reads

Marriage Length at Conception and Schizophrenia Risk, Schizophr Res; ePub 2019 Mar 8; Malaspina, et al

Visual Hallucinations Linked with Illness Morbidity, Schizophr Res; ePub 2019 Mar 3; Chouinard, et al

Avoiding Incorrect Diagnoses of Schizophrenia, J Psychiatr Pract; 2019 Mar; Coulter, Baker, et al

Sleep Disturbances Common in Schizophrenia, Compr Psychiatry; 2019 May; Laskamoen, et al

Social Cognition in the Early Stage Schizophrenia, Psychiatry Res; 2019 Feb; Mike, Guimond, et al

Must Reads in ADHD

Nighttime Media Use in Adolescents with ADHD, Sleep Med; ePub 2018 Jul 28; Becker, Lienesch

Can Birth Season Predict ADHD in Early Midlife?, Psychiatry Res; ePub 2018 Jun 6; Zhang, et al

FDA Approves ADHD Drug for Patients 6 and Older, Neos Therapeutics news release; 2017 Sep 15

ADHD, CU Traits Markers for Conduct Problems, Psychiatry Res; ePub 2017 Sep 5; Babinski, et al